Cystic Fibrosis. (a) Notwithstanding anything to the contrary contained herein, the provisions of Sections 2.13.1, 2.13.2 and 2.13.3 will not apply with respect to the discovery, research, development, manufacture or commercialization of any product for the treatment of cystic fibrosis by Vertex or its Affiliates and Vertex and its Affiliates will not be restricted from conducting such activities.
Cystic Fibrosis. Vertex’s Option with respect to Cystic Fibrosis may be exercised at any time prior to the date that is [***] following the later of (a) the conclusion of the first two years of the Research Term or (b) the conclusion of the last Research Extension for the Cystic Fibrosis Research Program (as applicable); provided that, prior to the exercise of the Option for Cystic Fibrosis, Vertex shall have the right to evaluate the Capsids in [***], and provided further, that if Vertex is so evaluating a Capsid(s) for Cystic Fibrosis on the date that is [***] following the later of (a) or (b) above, or is scheduled to commence such evaluation within [***] thereafter, then the Option will expire upon the earlier of (i) [***] after Vertex’s receipt of the final data from such evaluation, or (ii) [***] following the later of (A) the conclusion of the first two years of the Research Term or (B) the conclusion of the last Research Extension for the Cystic Fibrosis Research Program (as applicable) (such period, the “CF Option Exercise Period”). Upon timely notice to Company during the CF Option Exercise Period that Vertex wishes to exercise the Option for Cystic Fibrosis and payment to Company of a one-time, non-refundable, non-creditable option exercise fee of [***] (the “CF Option Fee”), the covenant set forth in Section 4.7.2 with respect to Cystic Fibrosis shall expire. For the avoidance of doubt, Vertex’s exercise of the Option for Cystic Fibrosis shall not affect Company’s obligation to conduct Research Activities with respect to Cystic Fibrosis in accordance with Section 2.1 during the first two years of the Research Term and during any applicable Research Extension for the Cystic Fibrosis Research Program, as applicable. If Vertex does not make a timely exercise of the Option for Cystic Fibrosis during the CF Option Exercise Period, the Option for Cystic Fibrosis will lapse and the diagnosis, treatment and prevention of Cystic Fibrosis shall no longer be included in the Field, effective as of the conclusion of the CF Option Exercise Period, and any and all rights granted hereunder by Company to Vertex with respect to Cystic Fibrosis as a Vertex Disease will revert automatically to Company, and all exclusivity obligations of Company and its Affiliates and successors under Section 4.7.1 with respect to Cystic Fibrosis shall automatically terminate. [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOT...
Cystic Fibrosis. Impact Treatment Do you get exhausted when you do sports? Do you feel tired during the day? Do you get out of breath? Do you need to rest more than others? Does it bother you that you must take your enzymes before every meal? Does it bother you that you have to eat a special diet to keep you healthy? Does it bother you that you have to spend a lot of time having treatment? Are you bothered because you have to do physiotherapy everyday? Have you felt that your treatment takes up too much of your free time? Do you feel bothered that you have to stop playing or doing things for treatment? Impact Treatment Does diabetes stop you from doing the things you want to do? Does diabetes rule your day? Does it bother you that you have to be careful about what you eat? Is it difficult for you to stick to your diet? Do you worry about your blood sugar level? Does it bother you that others can always eat and drink as much as they like? Are you annoyed that you have to carry the testing equipment with you? Are you bothered that you have to plan everything? Do you mind taking insulin? Do you get fed up with measuring your blood sugar levels?
Cystic Fibrosis. (a) Notwithstanding anything to the contrary contained herein, the provisions of Sections 2.13.1, 2.13.2 and 2.13.3 will not apply with respect to the discovery,
Cystic Fibrosis. (a) Notwithstanding anything to the contrary contained herein, the provisions of Sections 2.13.1, 2.13.2 and 2.13.3 will not apply with respect to the discovery, Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. research, development, manufacture or commercialization of any product for the treatment of cystic fibrosis by Vertex or its Affiliates and Vertex and its Affiliates will not be restricted from conducting such activities.
Cystic Fibrosis. Understand the general pediatrician's role in the management of cystic fibrosis. Discuss the presenting signs and symptoms of cystic fibrosis and refer the patient for appropriate confirmatorytesting, education, and treatment. Discussion should include high-risk populations, associated symptoms, treatment options and expected course of the disease. Participate in development and implementation of a coordinated pulmonary and nutritional treatment plan for a patient with cystic fibrosis, including recognition and treatment of acute episodic illnesses, nutritional deficiencies, intestinal obstruction and psychosocial issues. Discuss the multidisciplinary approach to cysticfibrosis care and the role of the general pediatrician. Identify indicators that signify an exacerbation of pulmonary symptoms. Provide appropriate initial treatment and referral to a specialty center for further evaluation and treatment. GOAL: Pediatric Competencies. Demonstrate high standards of professional competence while working with patients under the care of a subspecialist.
